-
1.发明公开
公开(公告)号：EP1511484A1
公开(公告)日：2005-03-09
申请号：EP03755149.6
申请日：2003-05-28
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/454 , A61K31/40 , A61K31/16 , A61P3/10 , A61K31/41
CPC分类号： A61K31/454 , A61K31/16 , A61K31/40 , A61K31/41
摘要： The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and a cardiovascular compound (being different from a statin) or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of diseases and disorders selected from the group consisting of hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetes, especially type 2 diabetes mellitus, diabetic retinophathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertryglyceridemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance.
-
2.发明授权THE USE OF SUBSTITUTED CYANOPYRROLIDINES FOR TREATING HYPERLIPIDEMIA 有权取代CYANOPYRROLIDINEN用于治疗高脂血症USE
公开(公告)号：EP1513519B1
公开(公告)日：2009-02-18
申请号：EP03737984.9
申请日：2003-06-02
申请人： NOVARTIS AG , Novartis Pharma GmbH
CPC分类号： A61K31/401 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantyl; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier.
-
公开(公告)号：EP1928499A1
公开(公告)日：2008-06-11
申请号：EP06803805.8
申请日：2006-09-18
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： A61K45/06
CPC分类号： A61K45/06 , A61K31/155 , A61K31/64 , A61K38/28 , A61K2300/00
摘要： The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.
-
4.发明授权COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS 有权组合物，包含二肽基肽酶IV抑制剂和抗糖尿病药物
公开(公告)号：EP1248604B2
公开(公告)日：2012-02-29
申请号：EP01909661.9
申请日：2001-01-19
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K45/06 , A61P3/10 , A61K31/00 , A61K31/4025 , A61K31/44 , A61K31/505
CPC分类号： A61K45/06 , A61K31/00 , A61K31/4025 , A61K31/44 , A61K31/505 , A61K2300/00
摘要： The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase - IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
-
5.发明公开
公开(公告)号：EP1513519A1
公开(公告)日：2005-03-16
申请号：EP03737984.9
申请日：2003-06-02
申请人： Novartis AG , Novartis Pharma GmbH
CPC分类号： A61K31/401 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantyl; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier.
-
公开(公告)号：EP1928499B1
公开(公告)日：2011-06-29
申请号：EP06803805.8
申请日：2006-09-18
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K45/06
CPC分类号： A61K45/06 , A61K31/155 , A61K31/64 , A61K38/28 , A61K2300/00
摘要： The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.
-
7.发明授权COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS 有权组合物，包含二肽基肽酶IV抑制剂和抗糖尿病药物
公开(公告)号：EP1248604B1
公开(公告)日：2006-11-29
申请号：EP01909661.9
申请日：2001-01-19
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K45/00 , A61K31/401 , A61P3/10
CPC分类号： A61K45/06 , A61K31/00 , A61K31/4025 , A61K31/44 , A61K31/505 , A61K2300/00
摘要： The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase - IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
-
8.发明公开COMBINATION OF A DPP IV INHIBITOR AND AN ANTI-OBESITY OR APPETITE REGULATING AGENT 审中-公开的DPP-IV抑制剂UDN抗肥胖剂或食欲的组合
公开(公告)号：EP1687030A2
公开(公告)日：2006-08-09
申请号：EP04797931.5
申请日：2004-11-16
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K45/06 , A61K31/4025 , A61K31/40 , A61K31/401 , A61P3/00 , A61P9/00 , A61P17/00 , A61P27/00
CPC分类号： A61K45/06 , A61K31/137 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/4439 , A61K31/47 , A61K31/4704 , A61K2300/00
摘要： The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and an antiobesity agent, or an appetite regulating agent, or a pharmaceutically acceptable salt thereof.. The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of diseases and disorders selected from the group consisting of hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertryglyceridemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance.
-
9.发明公开COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS 有权组合物，包含二肽基肽酶IV抑制剂和抗糖尿病药物
公开(公告)号：EP1248604A2
公开(公告)日：2002-10-16
申请号：EP01909661.9
申请日：2001-01-19
申请人： Novartis AG
IPC分类号： A61K31/00
CPC分类号： A61K45/06 , A61K31/00 , A61K31/4025 , A61K31/44 , A61K31/505 , A61K2300/00
摘要： The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase - IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.017 秒)
